TWiV 1044: Clinical update with Dr. Daniel Griffin

In his weekly clinical update, Dr. Griffin discusses the immunogenicity and reactogenicity of coadministration of COVID-19 and Influenza vaccines, interim effectiveness estimates of 2023 southern hemisphere influenza vaccines in preventing Influenza-associated hospitalizations, genome-wide association study of susceptibility to RSV hospitalization in young children <5 years of age, performance of rapid antigen tests to detect symptomatic and asymptomatic SARS-CoV-2 infection, safety and immunogenicity of XBB.1.5-containing mRNA vaccines, optimal duration of systemic corticosteroids in COVID-19 treatment, timing and predictors of loss of infectivity among healthcare workers with mild primary and recurrent COVID-19, and effects of famotidine on cognitive and behavioral dysfunctions induced in post-COVID-19 infection.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Immunogenicity and reactogenicity of coadministration of COVID-19 and Influenza vaccines (JAMA)
• Effectiveness estimates of Influenza vaccines in preventing associated hospitalizations (CDC)
• Genome-wide association study of susceptibility to RSV hospitalization in children (JID)
• Performance of rapid antigen tests to detect SARS-CoV-2 infection (AIN)
• Safety and immunogenicity of XBB.1.5-containing mRNA vaccines (medRxiv)
• C.D.C. director explains why you should get the latest Covid booster (Nytimes)
• Optimal duration of systemic corticosteroids in COVID-19 treatment (OFID)
• Timing and predictors of loss of infectivity among healthcare workers with COVID-19 (CID)
• Effect of famotidine on cognitive and behavioral dysfunctions induced in post-COVID-19 infection (JPR)
• Contribute to our Floating Doctors fundraiser at PWB
• Letters read on TWiV 1044
• Dr. Griffin's COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]